clears US FDA inspection of Nagpur facility with zero issues Lupin's Nagpur facility passed a US FDA inspection with "No Observations" after a 4-day inspection from November 10 to 14, 2025. This is a zero-FDA 483 observation outcome, a notice for potential regulatory violations. Revenue grew by 24.2% y-o-y to ₹7,047.5 crore and net profit surged by 73.34% y-o-y to ₹1,478 crore. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.